- Home
- OBE vs SGP Comparison
OBE vs SGP Comparison
Compare OBE & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBE | SGP |
|---|---|---|
| Founded | 1979 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 865.4M | 968.0M |
| IPO Year | 2005 | 2026 |
Fundamental Metrics
Financial Performance| Metric | OBE | SGP |
|---|---|---|
| Price | $10.67 | $27.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $10.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 792.0K | 105.2K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.21 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.44 | $17.06 |
| 52 Week High | $14.59 | $30.56 |
Technical Indicators
Market Signals| Indicator | OBE | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 47.87 |
| Support Level | $9.18 | $27.00 |
| Resistance Level | $10.92 | $29.90 |
| Average True Range (ATR) | 0.63 | 1.66 |
| MACD | -0.24 | -0.31 |
| Stochastic Oscillator | 7.57 | 11.14 |
Price Performance
Historical ComparisonAbout OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Sale of Oil.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.